Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP3A41G and CYP3A53 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation .

International journal of clinical pharmacology and therapeutics - 1 Feb 2017

Huang Yun, Wen Gaiyan, Lu Yao, Wen Jia, Ji Ying, Xing Xiaowei, Li Ying, Wen Juan, Yuan Hong

Abstract excerpt

OBJECTIVE: Previous studies have determined that CYP3A and multidrug resistance protein 1 (MDR1) polymorphisms can affect the pharmacokinetics and pharmacodynamics of amlodipine in both healthy subjects and those with early hypertensive renal disease. In the current study, our objective was to analyze the association between the CYP3A4*1G, CYP3A5*3, and MDR1 C3435T gene polymorphisms and the antihypertensive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antihypertensive Agents
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Pressure

Share to Calcium Channel Blockers

Share to Cytochrome P-450 CYP3A

Share to Kidney Transplantation

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Source

Identifiers

PMID: 27841150
DOI: 10.5414/CP202559

Genes

DBP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation .PMID 27841150Read ↗

CYP3A5 polymorphism, amlodipine and hypertension.Semantic proximity Read ↗

Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy.Semantic proximity Read ↗

Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients.Semantic proximity Read ↗

CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.Semantic proximity Read ↗

[Gene polymorphisms of CYP3A5 and MDR-1 in Hans renal transplant recipients in Hunan Province].Semantic proximity Read ↗

Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors.Semantic proximity Read ↗

CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults.Semantic proximity Read ↗

Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.Semantic proximity Read ↗

Influence of G-protein β-Polypeptide 3 C825T Polymorphism on Antihypertensive Response to Telmisartan and Amlodipine in Chinese Patients.Semantic proximity Read ↗

The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients.Semantic proximity Read ↗

Association of CYP3A5 Gene Polymorphisms and Amlodipine-Induced Peripheral Edema in Chinese Han Patients with Essential HypertensionSemantic proximity Read ↗

Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.